OLMA

Olema Pharmaceuticals, Inc.

Fundamental data last updated:October 11, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

 


Analyze OLMA on TradingView

VALUATION

P/E

-7.08

Market Cap ($M USD)

$1.11B

Forward P/E

36.72

PEG

0.31

PRICE TO SALES

0.00

PRICE TO BOOK

2.73

EV / EBITDA

-5.38

5-Year Average P/E

Free Cash Flow Yield

-13.34%

DCF Value

$0.49

Graham Number

N/A

Price to FCF

-7.49

EV to FCF

-7.15

Earnings Yield

-14.12%

FCF Yield

-13.34%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.80

Next Year EPS Growth Estimate

$0.35

Next Year Revenue Growth Estimate

$536.62M

Return on Equity (ROE)

-45.95%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.00

Piotroski F-Score

1

Altman Z-Score

12.40

Return on Invested Capital (ROIC)

-41.74%

Current Ratio

10.88

Quick Ratio

10.88

Net Debt to EBITDA

0.26

Interest Coverage

0.00

Gross Profit margin

0.00%

FCF PER SHARE

$-1.45

REVENUE PER SHARE

$0.00

Analyze OLMA on TradingView

Gainseekers Quantitative Analysis

Summary

Olema Pharmaceuticals, Inc. presents a perplexing valuation picture. Despite a staggering Altman Z-score of 12.80, indicating financial stability, the stock’s market price has been significantly below its DCF value. The Forward P/E of 25.80 suggests optimism for future earnings, yet the negative Earnings Yield and ROIC highlight current profitability challenges. The market seems to be pricing in a turnaround, but the negative Price to FCF and a Piotroski F-Score of 1 raise red flags about operational efficiency and growth execution.

AI Exposure / Tech Reliance

In the rapidly evolving biotechnology sector, Olema Pharmaceuticals is well-positioned to leverage AI and modern tech advancements. The industry’s inherent focus on innovation and research provides a fertile ground for integrating AI-driven drug discovery and personalized medicine. This adaptability could enhance their competitive edge and streamline R&D processes.

The Bull Case

For the bullish investor, Olema's appeal lies in its potential for explosive growth, as evidenced by the astronomical projected sales growth. The low Debt/Equity ratio of 0.0025 and a robust Current Ratio of 9.95 suggest a strong liquidity position, providing a cushion for strategic investments. Despite a negative ROIC, the company's ability to pivot and capitalize on future earnings, as indicated by the Forward P/E, could offer substantial upside if management executes effectively.

The Bear Case

The bear case against Olema is formidable. The negative Price to FCF and FCF Yield underscore a troubling cash flow situation, while the Price/Book ratio of 2.84 suggests the stock isn't cheap. With a Return on Equity of -42.90%, the company struggles to generate shareholder value. Additionally, trading significantly below its 50-Day and 200-Day SMAs indicates technical weakness, further compounded by a lack of gross profit margin and zero operating margin.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$41.88

Institutional Ownership %

1-Year Beta

2.06

Insider Buying % (6 Mo)

Distance to 52-Week High

184.16%

Distance to 52-Week Low

69.51%

EARNINGS SURPRISE %

0.00%

50-DAY SMA

$14.74

200-DAY SMA

$16.69

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.